The future of treating metabolic dysfunction–associated steatohepatitis (MASH) looks brighter than ever, says Naim Alkhouri, MD, as data emerges on newly developed interventions.

Short term trials with surrogate measures instead of hard outcomes are often used to study chronic diseases. The effects of an intervention may, however, take time to develop and persist after ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Palatin has announced positive results from its BMT-801 Phase II clinical trial of co-administered melanocortin-4 receptor (MC4R) agonist bremelanotide plus glucagon like peptide-1/gastric inhibitory ...

both alone and in combination with the glucagon-like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) tirzepatide. The study demonstrated significant improvements in appetite suppression ...

Moreover, companies like Viking Therapeutics are advancing a new platform that combines GLP-1 and gastric inhibitory polypeptide (GIP) agonists. Recent data suggests this combination has the ...

Primary endpoint met in the 8-week treatment study (highly statistically significant). Co-administered group had a 4.4% reduction in weight compared to 1.6% for the placebo group (p<0.0001).